Latest Conference Articles

Ociperlimab plus tislelizumab revealed promising efficacy in adults with treatment-naïve, metastatic, PD-L1–positive non­–small cell lung cancer.

First-line durvalumab in combination with tremelimumab improved overall survival vs standard-of-care chemotherapy for the treatment of patients with metastatic non–small cell lung cancer.

Tremelimumab plus durvalumab and chemotherapy displayed improvements in clinical and survival benefit in patients with PD-L1 negative metastatic non–small cell lung cancer.

Larotrectinib continued to demonstrate favorable efficacy and survival outcomes with low toxicity, according to extended follow-up for 2 trials of patients with lung cancer and NTRK fusions.

Aaron T. Gerds, MD, MS, discusses the clinical trial development of momelotinib, a JAK1/JAK2 inhibitor that is being investigated for the treatment of patients with myelofibrosis.

The addition of zanubrutinib to obinutuzumab in patients with relapsed/refractory follicular lymphoma demonstrated improved overall response rates, progression-free survival, and overall survival.

Rivoceranib showed promising responses in regard to objective response rate and disease control rate when used in patients with recurrent or metastatic adenoid cystic carcinoma.

Dostarlimab monotherapy induced durable antitumor activity in advanced or recurrent endometrial cancer among patients with mismatch repair deficient/microsatellite instability–high or mismatch repair proficient/mismatch stable disease, according to data from 2 expansion cohorts in the GARNET trial.

At the 2022 ASCO Annual Meeting, utilizing matching-adjusted indirect comparison, researchers showed the survival benefit of larotrectinib in patients with TRK fusion-positive tumors.

Selinexor has demonstrated improvement in progression-free survival over placebo in patients with advanced or recurrent endometrial cancer.

Reduced risk of metastatic progression and improved overall survival seen with darolutamide in patients with nonmetastatic castration-resistant prostate cancer.

FOLFOXIRI plus panitumumab should not be recommended as upfront therapy for RAS and BRAF wild-type mCRC patients. according to investigators of the phase 3 TRIPLETE study.

According to Timothy J. Whelan, MD, FASCO, radiotherapy is an inconvenient treatment. It can last daily for up to 5 weeks and it is a costly therapy. Study results shows that is can safely be omitted in the treatment of some patients with luminal A breast cancers.

Phase 3 CAIRO5 showed improvements in progression-free survival and overall response with FOLFOXIRI plus bevacizumab in colorectal cancer liver metastases, but the combination demonstrated a toxic safety profile.

At the 2022 ASCO Annual Meeting, results from the GEMSTONE-302 trial showed that adding sugemalimab to chemotherapy improved survival in patients with metastatic non–small cell lung cancer.

Potential biomarkers of overall survival outcomes have been identified in an exploratory post-hoc analysis of the phase 3 TITAN trial.

According to Conor E. Steuer, MD, patritumab deruxtecan showed promising clinical activity in heavily pretreated patients with advanced non–small cell lung cancer with or without identified variant genomic alterations.

Ruxolitinib and chemotherapy appeared to boost progression-free survival in patients with stage III and IV ovarian cancer when given before or after surgery.

Several key risk factors seen in the monarchE trial of adjuvant abemaciclib could help early monitoring of patients with hormone receptor–positive, HER2-negative, node-positive high-risk early breast cancer to prevent discontinuation.

Dafrafenib plus trametinib demonstrated greatly improved response rates and progression-free survival in pediatric patients with BRAF V600-mutated gliomas.

Patients with advanced lung cancer harboring neurotrophic tyrosine receptor kinase gene fusions treated with larotrectinib demonstrated positive efficacy and safety.

Results from the RELATIVITY-047 trial showed improved progression-free survival for patients with advanced melanoma who received nivolumab plus relatlimab.

Correlations between non–small cell lung cancer the metastasizes to the brain and enriched CDKN2A/B and EGFR alterations calls for further genomic exploration of this patient population.

Adjuvant pembrolizumab led to improved disease-free survival versus placebo in patients with fully resected non–small cell lung cancer, according to second interim results from the PEARLS/KEYNOTE-091 trial.

Bevacizumab improved progression-free survival and overall survival when added to frontline chemotherapy in patients with advanced ovarian clear cell carcinoma, according to a retrospective analysis of patients treated in Japan from 2008 to 2018.

Three-year follow-up of the CheckMate 9LA trial shows continued survival benefit to nivolumab/ipilimumab plus 2 cycles of chemotherapy in patients with metastatic non–small cell lung cancer.

Results from the KEYNOTE-826 trial showed that chemotherapy plus pembrolizumab with or without bevacizumab improved overall survival and progrssion-free survival in patients with metastatic cervical cancer based on subgroups including histology and prior treatment type.

The 5-year analysis of the CheckMate 227 study shows long-term survival benefit for nivolumab plus ipilimumab versus chemotherapy in patients with metastatic non–small cell lung cancer.

Patients with platinum-sensitive ovarian cancer treated with maintenance rucaparib in the ATHENA-MONO trial showed a significant improvement in progression-free survival when compared with placebo in the first-line setting, regardless of HRD status.

In patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer that has progressed after mobocertinib treatment, remaining on mobocertinib may be warranted, according to news research.